Apolipoprotein B Above or Below the Reference Range: Causes in Athletes and What to Do

Apolipoprotein B, usually shortened to apoB, is increasingly offered in private blood panels in the UK. It gives a count of the particles that can enter artery walls and start atherosclerosis. For athletes it can reveal risk that a "good" cholesterol result hides, or reassure when other numbers look odd. Here is how to interpret it.
What apoB measures
Cholesterol and triglycerides travel in the blood inside lipoprotein particles. Each LDL, VLDL, IDL and lipoprotein(a) particle carries exactly one apoB molecule, so the apoB concentration is effectively a count of these atherogenic particles.
Standard tests measure the amount of cholesterol inside particles, such as LDL cholesterol. When particles are small and cholesterol-poor, LDL cholesterol can look acceptable while the particle number is high. ApoB captures that difference.
A narrative review by Sniderman and colleagues argued that apoB is the most accurate single marker of risk from atherogenic lipoproteins, and the European ESC/EAS guidelines list it as a recommended secondary target.
In the UK, apoB is not part of routine NHS lipid screening. It is available in many laboratories and private panels, and specialists may request it in particular situations, such as high triglycerides or diabetes.
High apoB: common causes in athletes
Raised apoB indicates more atherogenic particles. Causes overlap with those of high LDL cholesterol but may also involve triglyceride-rich particles.
| Cause | Typical pattern | Notes |
|---|---|---|
| Inherited (e.g. familial hypercholesterolaemia) | Markedly high apoB and LDL-C from youth | Family history of early heart disease |
| Anabolic-androgenic steroids | Higher LDL and apoB, sharply lower HDL | Documented in user studies |
| Diet high in saturated fat | Moderate increase | Common in high-calorie bulking diets |
| Insulin resistance, excess visceral fat | High triglycerides, small dense LDL | ApoB often higher than LDL-C suggests |
| Hypothyroidism, kidney or liver conditions | Variable | Secondary causes to exclude |
Hartgens and colleagues showed that anabolic steroid use in strength athletes changed apolipoproteins unfavourably, including falls in apoA-I, the main HDL protein. The Endocrine Society statement by Pope and colleagues lists dyslipidaemia among the important cardiovascular consequences.
Bulking diets built around large amounts of butter, cheese, fatty meat and coconut oil can raise apoB, even in lean, active people. Training does not cancel out this dietary effect.
Fitness can mask risk. A low resting heart rate and good body composition say little about particle number, which is why a blood test is valuable for experienced lifters.

Low apoB: when it matters
Low apoB is generally associated with lower cardiovascular risk. In people taking statins or other lipid-lowering medicines it is an expected effect.
Very low values without treatment, however, may reflect other conditions:
- Low energy availability or malnutrition, including relative energy deficiency in sport (RED-S).
- Overactive thyroid.
- Significant liver disease reducing lipoprotein production.
- Rare inherited hypobetalipoproteinaemia, which can affect absorption of fat-soluble vitamins.
- Malabsorption conditions such as coeliac disease.
In endurance athletes with a very low body weight, menstrual disturbances or recurrent injuries, a low apoB result is one more clue to look at overall energy intake.
If apoB is unexpectedly very low, a GP may check thyroid and liver function and assess vitamin levels before concluding that it is simply a favourable result.
Targets and interpretation
ESC/EAS guidance links apoB targets to overall cardiovascular risk, with lower targets for higher-risk groups. In practice, results should be interpreted alongside LDL cholesterol, non-HDL cholesterol, triglycerides, blood pressure, smoking, family history and age.
NICE guideline NG238 on cardiovascular risk assessment focuses on non-HDL cholesterol, which correlates closely with apoB. When the two disagree, apoB tends to provide the better guide to particle-related risk.
Lipoprotein(a) is worth testing once in a lifetime, particularly with a family history of early heart disease. Because it also carries apoB, a high Lp(a) can partly explain a raised apoB.
The European Atherosclerosis Society consensus by Ference and colleagues emphasised that cumulative exposure to apoB-containing lipoproteins drives risk. In other words, years of moderately high levels matter as much as a single peak.
What to do next
A sensible approach to an abnormal apoB result includes:
- Repeat the test with standard conditions, including a lipid profile.
- Review diet, especially saturated fat intake during bulking phases.
- Be honest with the doctor about any anabolic steroid or other substance use.
- Exclude secondary causes: thyroid, kidney, liver and glucose tests.
- Discuss family history and whether genetic testing for familial hypercholesterolaemia is appropriate.
Lifestyle measures that lower apoB include replacing saturated fat with unsaturated fats, increasing soluble fibre, reducing excess body fat and limiting alcohol.
Where risk is high, lipid-lowering medication may be recommended. This is a clinical decision made with a GP or lipid specialist, based on overall risk rather than a single number.
For those who have used anabolic steroids, lipid changes often improve after stopping, but monitoring should continue, as cardiovascular effects may persist.
Conclusions of the editorial team
ApoB counts the particles that drive atherosclerosis and can reveal risk that LDL cholesterol alone underestimates.
In athletes, high apoB is most often linked to genetics, anabolic steroid use or high saturated fat intake; low apoB may signal low energy availability, thyroid or liver issues.
Interpret apoB in the context of the full lipid profile and overall risk, and discuss any abnormal result with a GP.
Related reading: lipoprotein(a) and why it is worth testing once, HDL cholesterol in strength athletes, and familial hypercholesterolaemia explained.
References
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–1295.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472.
- Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004;38(3):253–259.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238). London: NICE; 2023.


